Universal Beteiligungs und Servicegesellschaft mbH Invests $652,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH purchased 1,969 shares of Madrigal Pharmaceuticals, Inc. valued at approximately $652,000 during the first quarter, marking a new investment in the biopharmaceutical company.
• Madrigal Pharmaceuticals reported quarterly earnings of ($3.32) EPS, beating analysts' estimates, and generated $137.25 million in revenue, exceeding expectations by a significant margin.
• Recent upgrades from various research firms raised the price target for Madrigal Pharmaceuticals, with UBS Group increasing it to $458 and maintaining a "buy" rating, reflecting positive analyst sentiment towards the stock.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,969 shares of the biopharmaceutical company's stock, valued at approximately $652,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. VSM Wealth Advisory LLC purchased a new position in Madrigal Pharmaceuticals in the first quarter worth about $25,000. Farther Finance Advisors LLC raised its stake in shares of Madrigal Pharmaceuticals by 825.0% in the first quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 99 shares during the period. GAMMA Investing LLC raised its stake in shares of Madrigal Pharmaceuticals by 131.4% in the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 67 shares during the period. First Horizon Advisors Inc. raised its stake in shares of Madrigal Pharmaceuticals by 38.9% in the first quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 44 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Madrigal Pharmaceuticals by 42.7% in the first quarter. Parallel Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 85 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Stock Performance

Shares of Madrigal Pharmaceuticals stock traded up $9.94 on Monday, reaching $312.11. 404,909 shares of the stock were exchanged, compared to its average volume of 370,619. The company has a quick ratio of 5.58, a current ratio of 5.91 and a debt-to-equity ratio of 0.17. Madrigal Pharmaceuticals, Inc. has a twelve month low of $200.63 and a twelve month high of $377.46. The firm has a market capitalization of $6.93 billion, a price-to-earnings ratio of -17.29 and a beta of -1.02. The business has a 50 day moving average price of $295.25 and a two-hundred day moving average price of $312.01.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.62) by $0.30. Madrigal Pharmaceuticals had a negative return on equity of 50.54% and a negative net margin of 123.38%. The company had revenue of $137.25 million during the quarter, compared to the consensus estimate of $112.79 million. During the same period in the previous year, the company posted ($7.38) earnings per share. Analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, Director Rebecca Taub sold 26,444 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $353.47, for a total value of $9,347,160.68. Following the completion of the transaction, the director directly owned 461,044 shares of the company's stock, valued at approximately $162,965,222.68. The trade was a 5.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Paul A. Friedman sold 26,176 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $353.47, for a total value of $9,252,430.72. Following the transaction, the director directly owned 187,164 shares of the company's stock, valued at approximately $66,156,859.08. The trade was a 12.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,377 shares of company stock valued at $21,316,969 over the last three months. 21.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

MDGL has been the topic of several recent analyst reports. UBS Group lifted their target price on Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. JMP Securities reaffirmed a "market outperform" rating and issued a $443.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Thursday, April 24th. Canaccord Genuity Group upped their target price on Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Wall Street Zen raised Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th. Finally, B. Riley reissued a "buy" rating and issued a $460.00 price target (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $420.63.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.